9.2 Microbia-based therapy
For diseases whose pathogenesis involves dysregulation of the intestinal flora and disruption of the intestinal mucosal barrier, promising novel therapies are being developed. FMT is a good therapeutic strategy for treating Clostridioides difficile infection 125. However, its efficacy is limited by the host inflammatory immune status126. Side effects such as fever and a temporary increase in C-reactive protein levels after FMT deserves attention67. Defined bacterial consortia were selected based on their desired biological functions. Atarashi et al. isolated Treg cell-inducing bacterial strains 67. This strain alleviates colitis and allergic diarrhea in mice. Using defined bacterial consortia brings hope for tailoring therapeutic products for human immune disorders. The appointed combinations of microbes have more predictable responses, more targeted efficacy, and fewer adverse responses, such as infection by pathogens.